Adapting to a pandemic & an international clinical trial with diffuse optics
Marco Pagliazzi, ICFO-The Institute of Photonic Sciences, Spain
Lorenzo Cortese, ICFO-The Institute of Photonic Sciences, Spain
Umut Karadeniz, ICFO-The Institute of Photonic Sciences, Spain
Jaume Mesquida, Hospital de Sabadell, Institut Universitari Parc Taulí, Spain
Turgut Durduran, ICFO-The Institute of Photonic Sciences, Institució Catalana de Recerca i Estudis Avançats (ICREA), Spain
on behalf of the HEMOCOVID-19 consortium
Abstract
Early 2020 saw the spread of coronavirus disease 2019 (COVID-19) from a local outbreak to a worldwide pandemic. A crucial issue has been the surge in patients requiring intensive care unit (ICU) admission that has overwhelmed the healthcare systems. For CU management, which is critical in reducing both mortality and morbidity, the adequate management of acute respiratory failure and supporting the
hemodynamics is key. However, the most efficient form of ICU management related to the immense need for patient-specific strategies and the associated prognosis is unknown.
I will present the HEMOCOVID-19 project which emerged during the lock-down in Spain. Our collaboration spanning four countries and a dozen clinics uses near-infrared diffuse
optical technologies to non-invasively evaluate endothelial and
microvascular dysfunction to aid both the development of targeted
therapies and also to personalize rescue therapies. I will
present the project and the preliminary results. Finally, I will explain a new international collaboration that has been funded by the Horizon 2020 program of the European Commission within the emergency COVID-19 calls where a next generation device will be developed and tested working closely with the industry and academia.
Speaker
Turgut Durduran
ICFO-The Institute of Photonic Sciences
Spain
Discussion
Ask question
